Study wrapper · #35
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.
Editor's note
This 7-day rat study from Sikiric's group — the same prolific team behind most of the BPC-157 preclinical literature — examined whether BPC-157 could accelerate closure of surgically created tracheocutaneous fistulas and how that effect interacts with the nitric oxide (NO) system. Results showed that untreated control animals developed severe respiratory distress, open-mouth breathing, cyanosis, and failed wound healing, while BPC-157-treated rats (across both oral and intraperitoneal routes, at µg and ng doses) showed macroscopic and microscopic fistula closure alongside reduced clinical distress markers. The study also reported that BPC-157 appeared to modulate both NO and oxidative stress (MDA) levels in fistula tissue, and could counteract the effects of pharmacological NO blockade or over-activation.
These are preclinical findings in a rat model; human data are needed before clinical conclusions can be drawn. The 7-day window is short, the model is highly specific, and all work originates from one research group — independent replication is absent. The mechanistic framing around the NO system is consistent with the broader BPC-157 literature, which is almost entirely...
Plain-language abstract
Researchers created tracheocutaneous fistulas — abnormal openings connecting the trachea (windpipe) to the skin — in rats to study whether the synthetic peptide BPC-157 could help close them and to understand the role of the body's nitric oxide (NO) signalling system in that process.
Over 7 days, untreated control rats developed serious respiratory problems including open-mouth breathing, a visibly heaving abdomen from compensatory breathing effort, bluish discolouration of the snout, ears, and limbs (indicating poor oxygenation), heavy secretion through the fistula opening, and weight loss. The fistulas remained open and well-formed on both visible inspection and microscopic examination. Levels of a marker of oxidative stress (MDA) were elevated in fistula tissue, while NO levels were reduced.
Rats given BPC-157 — either dissolved in drinking water or injected into the abdomen, at two different doses — showed fistula closure and healing of both skin and tracheal tissue within the same 7-day window, with reduced signs of breathing difficulty and less weight loss. When BPC-157 was combined with drugs that either blocked or amplified NO signalling, it appeared to counteract the worsening caused by NO blockade and enhance the improvement seen with NO activation.
The abstract did not report adverse events in BPC-157-treated animals. These are preclinical findings in a rat model; human data are needed before any clinical conclusions can be drawn.